Healthcare / Pharmaceutical RetailersJohannesburg
$23652.00
+106.00 (+0.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.3B
P/E
16.7x
↓EV/EBITDA
941.1x
↑ROE
45.1%
↑Gross Margin
23.4%
↓Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
+9.3%
FCF margin
4.7%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $45.44B · net income $2.84B · FCF $2.12B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $45.44B | $45.44B | $41.62B | $39.59B | $37.34B |
| Net Income | $2.84B | $2.84B | $2.54B | $2.64B | $1.84B |
| EBITDA | $5.99B | $5.99B | $5.22B | $5.22B | $4.12B |
| EPS | 11.90 | 11.90 | 10.42 | 10.80 | 7.44 |
| Gross Margin | 23.4% | 23.4% | 22.4% | 21.3% | 19.5% |
| Operating Margin | 9.2% | 9.2% | 8.7% | 8.4% | — |
| Net Margin | 6.2% | 6.2% | 6.1% | 6.7% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.54 | 0.54 | 0.61 |
| Current Ratio | 1.05 | 1.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.12B | $2.12B | $2.38B | $1.08B | $1.62B |
| Returns | |||||
| ROE | 45.1% | 45.1% | 42.5% | 46.3% | 38.2% |
| Valuation | |||||
| P/E | 16.74 | 16.74 | 2560.30 | 2733.91 | 4055.66 |
| EV/EBITDA | 941.13 | 941.13 | 1244.37 | 1381.15 | 1808.18 |
| P/B | 896.88 | 896.88 | 1089.22 | 1265.90 | 1551.14 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | 5.1% | 6.0% | — |
| EPS Growth | 14.2% | 14.2% | -3.5% | 45.2% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
460.7%
EPS terminal req.
$2098.72
Spread vs growth
-446.5%
5Y implied EPS CAGR
192.3%
EPS terminal req.
$2539.45
Spread vs growth
-178.1%
10Y implied EPS CAGR
79.3%
EPS terminal req.
$4089.81
Spread vs growth
-65.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.2%
Start / end P/E
3664.4x → 1987.1x
EPS bridge
10.42 → 11.90
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.